Aumake (ASX:AUK) has secured a Hong Kong pharmaceutical wholesale licence, paving the way for the company's expansion into China's high-growth over-the-counter medicine and health products sector.
The licence allows Aumake to establish up to five compliant online OTC stores on major e-commerce platforms, with an option to acquire a second licence to add five more stores, providing a scalable pathway for national expansion.
This strategic move positions Aumake to capitalize on China's expanding OTC market, valued at over US$230 billion annually, where online sales now account for approximately 30% of total revenue, up from 8% in 2020.
The shift reflects broader structural reforms in China’s healthcare system, including reduced hospital provision of minor-condition medications, growing consumer demand for safe and imported OTC products, and regulatory support for cross-border online sales.
Leveraging its experience in cross-border commerce, proven e-commerce capabilities, and partnerships with leading international OTC brands, Aumake aims to accelerate its entry into this sector.
Non-Executive Chairman Dr. Anthony Noble highlighted the expansion as a key strategic pillar, noting that the OTC segment complements the company's higher-margin focus and scalable infrastructure, marking a significant step toward faster growth and profitability in 2026.
At the time of reporting, Aumake's share price was $0.0020.